{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:44:19Z","timestamp":1793105059648,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["MIDRP"],"award-info":[{"award-number":["MIDRP"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"USAID and US DoD"},{"name":"US DoD, USAID"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The Circumsporozoite Protein (CSP) of\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    contains an N-terminal region, a conserved Region I (RI), a junctional region, 25\u201342 copies of major (NPNA) and minor repeats followed by a C-terminal domain. The recently approved malaria vaccine, RTS,S\/AS01 contains NPNAx19 and the C-terminal region of CSP. The efficacy of RTS,S against natural infection is low and short-lived, and mapping epitopes of inhibitory monoclonal antibodies may allow for rational improvement of CSP vaccines. Tobacco Mosaic Virus (TMV) was used here to display the junctional epitope (mAb CIS43), Region I (mAb 5D5), NPNAx5, and NPNAx20 epitope of CSP (mAbs 317 and 580). Protection studies in mice revealed that Region I did not elicit protective antibodies, and polyclonal antibodies against the junctional epitope showed equivalent protection to NPNAx5. Combining the junctional and NPNAx5 epitopes reduced immunogenicity and efficacy, and increasing the repeat valency to NPNAx20 did not improve upon NPNAx5. TMV was confirmed as a versatile vaccine platform for displaying small epitopes defined by neutralizing mAbs. We show that polyclonal antibodies against engineered VLPs can recapitulate the binding specificity of the mAbs and immune-focusing by reducing the structural complexity of an epitope may be superior to immune-broadening as a vaccine design approach. Most importantly the junctional and restricted valency NPNA epitopes can be the basis for developing highly effective second-generation malaria vaccine candidates.\n                  <\/jats:p>","DOI":"10.1038\/s41541-022-00430-y","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T06:03:15Z","timestamp":1643263395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum"],"prefix":"10.1038","volume":"7","author":[{"given":"Mark D.","family":"Langowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhat A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofya","family":"Savransky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dallas R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arasu","family":"Balasubramaniyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2074-2373","authenticated-orcid":false,"given":"Gary R.","family":"Matyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Regules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine A.","family":"Soisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian H.","family":"Batchelor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-1880","authenticated-orcid":false,"given":"Sheetij","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"430_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1473-3099(15)70124-6","volume":"15","author":"PG Walker","year":"2015","unstructured":"Walker, P. G. et al. Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: A modelling analysis. Lancet Infect. Dis. 15, 825\u2013832 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"430_CR2","doi-asserted-by":"publisher","first-page":"l5501","DOI":"10.1136\/bmj.l5501","volume":"366","author":"E Mahase","year":"2019","unstructured":"Mahase, E. Malaria could be eradicated by 2050, say global experts. Bmj 366, l5501 (2019).","journal-title":"Bmj"},{"key":"430_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1084\/jem.20040989","volume":"201","author":"A Coppi","year":"2005","unstructured":"Coppi, A., Pinzon-Ortiz, C., Hutter, C. & Sinnis, P. The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J. Exp. Med. 201, 27\u201333 (2005).","journal-title":"J. Exp. Med."},{"key":"430_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/srep01990","volume":"3","author":"NM Bowman","year":"2013","unstructured":"Bowman, N. M. et al. Comparative population structure of Plasmodium falciparum circumsporozoite protein NANP repeat lengths in Lilongwe, Malawi. Sci. Rep. 3, 1990 (2013).","journal-title":"Sci. Rep."},{"key":"430_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0166-6851(87)90073-9","volume":"22","author":"MJ Lockyer","year":"1987","unstructured":"Lockyer, M. J. & Schwarz, R. T. Strain variation in the circumsporozoite protein gene of Plasmodium falciparum. Mol. Biochem. Parasitol. 22, 101\u2013108 (1987).","journal-title":"Mol. Biochem. Parasitol."},{"key":"430_CR6","doi-asserted-by":"publisher","first-page":"7817","DOI":"10.1073\/pnas.1205737109","volume":"109","author":"MB Doud","year":"2012","unstructured":"Doud, M. B. et al. Unexpected fold in the circumsporozoite protein target of malaria vaccines. Proc. Natl Acad. Sci. USA 109, 7817\u20137822 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"430_CR7","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.4161\/hv.29375","volume":"10","author":"G Leroux-Roels","year":"2014","unstructured":"Leroux-Roels, G. et al. Evaluation of the immune response to RTS,S\/AS01 and RTS,S\/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-na\u00efve adults. Hum. Vaccine Immunother. 10, 2211\u20132219 (2014).","journal-title":"Hum. Vaccine Immunother."},{"key":"430_CR8","doi-asserted-by":"crossref","unstructured":"World Health Organization. Malaria vaccine: WHO position paper, January 2016 - Recommendations. Vaccine 36, 3576\u20133577 (2018).","DOI":"10.1016\/j.vaccine.2016.10.047"},{"key":"430_CR9","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","volume":"365","author":"SCTP Rts","year":"2011","unstructured":"Rts, S. C. T. P. et al. First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863\u20131875 (2011).","journal-title":"N. Engl. J. Med."},{"key":"430_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/srep46621","volume":"7","author":"KA Collins","year":"2017","unstructured":"Collins, K. A., Snaith, R., Cottingham, M. G., Gilbert, S. C. & Hill, A. V. S. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci. Rep. 7, 46621 (2017).","journal-title":"Sci. Rep."},{"key":"430_CR11","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","volume":"397","author":"MS Datoo","year":"2021","unstructured":"Datoo, M. S. et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: A randomised controlled trial. Lancet 397, 1809\u20131818 (2021).","journal-title":"Lancet"},{"key":"430_CR12","doi-asserted-by":"publisher","unstructured":"Chatterjee, D. & Cockburn, I. A. The challenges of a circumsporozoite protein-based malaria vaccine. Expert. Rev. Vaccines https:\/\/doi.org\/10.1080\/14760584.2021.1874924 (2021).","DOI":"10.1080\/14760584.2021.1874924"},{"key":"430_CR13","doi-asserted-by":"publisher","first-page":"E10438","DOI":"10.1073\/pnas.1715812114","volume":"114","author":"D Oyen","year":"2017","unstructured":"Oyen, D. et al. Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein. Proc. Natl Acad. Sci. USA 114, E10438\u2013e10445 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"430_CR14","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1126\/science.aar5304","volume":"360","author":"K Imkeller","year":"2018","unstructured":"Imkeller, K. et al. Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. Science 360, 1358\u20131362 (2018).","journal-title":"Science"},{"key":"430_CR15","doi-asserted-by":"publisher","first-page":"eaau8529","DOI":"10.1126\/sciadv.aau8529","volume":"4","author":"D Oyen","year":"2018","unstructured":"Oyen, D. et al. Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts. Sci. Adv. 4, eaau8529 (2018).","journal-title":"Sci. Adv."},{"key":"430_CR16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408\u2013416 (2018).","journal-title":"Nat. Med."},{"key":"430_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm.4513","volume":"24","author":"J Tan","year":"2018","unstructured":"Tan, J. et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat. Med. 24, 401\u2013407 (2018).","journal-title":"Nat. Med."},{"key":"430_CR18","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.immuni.2017.11.007","volume":"47","author":"G Triller","year":"2017","unstructured":"Triller, G. et al. Natural parasite exposure induces protective human anti-malarial antibodies. Immunity 47, 1197\u20131209 (2017). e1110.","journal-title":"Immunity"},{"key":"430_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20170869","volume":"215","author":"SW Scally","year":"2018","unstructured":"Scally, S. W. et al. Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection. J. Exp. Med. 215, 63\u201375 (2018).","journal-title":"J. Exp. Med."},{"key":"430_CR20","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jmb.2019.12.029","volume":"432","author":"T Pholcharee","year":"2020","unstructured":"Pholcharee, T. et al. Diverse Antibody Responses to Conserved Structural Motifs in Plasmodium falciparum Circumsporozoite Protein. J. Mol. Biol. 432, 1048\u20131063 (2020).","journal-title":"J. Mol. Biol."},{"key":"430_CR21","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41591-020-0881-9","volume":"26","author":"R Murugan","year":"2020","unstructured":"Murugan, R. et al. Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs. Nat. Med. 26, 1135\u20131145 (2020).","journal-title":"Nat. Med."},{"key":"430_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","volume":"53","author":"LT Wang","year":"2020","unstructured":"Wang, L. T. et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity 53, 733\u2013744 (2020). e738.","journal-title":"Immunity"},{"key":"430_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84622-x","volume":"11","author":"MC Livingstone","year":"2021","unstructured":"Livingstone, M. C. et al. In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP). Sci. Rep. 11, 5318 (2021).","journal-title":"Sci. Rep."},{"key":"430_CR24","doi-asserted-by":"publisher","unstructured":"Francica, J. R. et al. Design of alphavirus virus-like particles presenting circumsporozoite junctional epitopes that elicit protection against malaria. Vaccines https:\/\/doi.org\/10.3390\/vaccines9030272 (2021).","DOI":"10.3390\/vaccines9030272"},{"key":"430_CR25","doi-asserted-by":"publisher","unstructured":"Phung, E. et al. Epitope-specific serological assays for RSV: Conformation matters. Vaccines https:\/\/doi.org\/10.3390\/vaccines7010023 (2019).","DOI":"10.3390\/vaccines7010023"},{"key":"430_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1126\/science.aav9033","volume":"365","author":"MC Crank","year":"2019","unstructured":"Crank, M. C. et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science 365, 505\u2013509 (2019).","journal-title":"Science"},{"key":"430_CR27","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1073\/pnas.1911792117","volume":"117","author":"MD Langowski","year":"2020","unstructured":"Langowski, M. D. et al. Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform. Proc. Natl Acad. Sci. USA 117, 3114\u20133122 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"430_CR28","doi-asserted-by":"publisher","first-page":"26951","DOI":"10.1074\/jbc.M109.013706","volume":"284","author":"ML Plassmeyer","year":"2009","unstructured":"Plassmeyer, M. L. et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J. Biol. Chem. 284, 26951\u201326963 (2009).","journal-title":"J. Biol. Chem."},{"key":"430_CR29","doi-asserted-by":"publisher","first-page":"7092","DOI":"10.1074\/jbc.M106862200","volume":"277","author":"D Rathore","year":"2002","unstructured":"Rathore, D., Sacci, J. B., de la Vega, P. & McCutchan, T. F. Binding and invasion of liver cells by Plasmodium falciparum sporozoites. Essential involvement of the amino terminus of circumsporozoite protein. J. Biol. Chem. 277, 7092\u20137098 (2002).","journal-title":"J. Biol. Chem."},{"key":"430_CR30","doi-asserted-by":"publisher","first-page":"40905","DOI":"10.1074\/jbc.M306250200","volume":"278","author":"D Rathore","year":"2003","unstructured":"Rathore, D. et al. Molecular mechanism of host specificity in Plasmodium falciparum infection: Role of circumsporozoite protein. J. Biol. Chem. 278, 40905\u201340910 (2003).","journal-title":"J. Biol. Chem."},{"key":"430_CR31","doi-asserted-by":"publisher","first-page":"e32524","DOI":"10.1371\/journal.pone.0032524","volume":"7","author":"C Aldrich","year":"2012","unstructured":"Aldrich, C. et al. Roles of the amino terminal region and repeat region of the Plasmodium berghei circumsporozoite protein in parasite infectivity. PLoS One 7, e32524 (2012).","journal-title":"PLoS One"},{"key":"430_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1084\/jem.20101488","volume":"208","author":"A Coppi","year":"2011","unstructured":"Coppi, A. et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J. Exp. Med. 208, 341\u2013356 (2011).","journal-title":"J. Exp. Med."},{"key":"430_CR33","doi-asserted-by":"publisher","first-page":"26784","DOI":"10.1074\/jbc.M104038200","volume":"276","author":"C Pinzon-Ortiz","year":"2001","unstructured":"Pinzon-Ortiz, C., Friedman, J., Esko, J. & Sinnis, P. The binding of the circumsporozoite protein to cell surface heparan sulfate proteoglycans is required for plasmodium sporozoite attachment to target cells. J. Biol. Chem. 276, 26784\u201326791 (2001).","journal-title":"J. Biol. Chem."},{"key":"430_CR34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.chom.2007.10.002","volume":"2","author":"A Coppi","year":"2007","unstructured":"Coppi, A. et al. Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells. Cell Host Microbe 2, 316\u2013327 (2007).","journal-title":"Cell Host Microbe"},{"key":"430_CR35","doi-asserted-by":"publisher","first-page":"20524","DOI":"10.1074\/jbc.M414254200","volume":"280","author":"D Rathore","year":"2005","unstructured":"Rathore, D. et al. An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J. Biol. Chem. 280, 20524\u201320529 (2005).","journal-title":"J. Biol. Chem."},{"key":"430_CR36","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.vaccine.2008.09.097","volume":"27","author":"SE Bongfen","year":"2009","unstructured":"Bongfen, S. E. et al. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 27, 328\u2013335 (2009).","journal-title":"Vaccine"},{"key":"430_CR37","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1016\/j.vaccine.2019.05.059","volume":"37","author":"A Cawlfield","year":"2019","unstructured":"Cawlfield, A. et al. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ). Vaccine 37, 3793\u20133803 (2019).","journal-title":"Vaccine"},{"key":"430_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-3014-5","volume":"18","author":"ML Martin","year":"2019","unstructured":"Martin, M. L. et al. Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013\/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin. Malar. J. 18, 377 (2019).","journal-title":"Malar. J."},{"key":"430_CR39","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.vaccine.2020.12.023","volume":"39","author":"DJ Friedman-Klabanoff","year":"2021","unstructured":"Friedman-Klabanoff, D. J. et al. Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing. Vaccine 39, 1195\u20131200 (2021).","journal-title":"Vaccine"},{"key":"430_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00274-4","volume":"6","author":"L Jel\u00ednkov\u00e1","year":"2021","unstructured":"Jel\u00ednkov\u00e1, L. et al. An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein. NPJ Vaccines 6, 13 (2021).","journal-title":"NPJ Vaccines"},{"key":"430_CR41","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/infdis\/jiv154","volume":"212","author":"DA Espinosa","year":"2015","unstructured":"Espinosa, D. A. et al. Proteolytic cleavage of the plasmodium falciparum circumsporozoite protein is a target of protective antibodies. J. Infect. Dis. 212, 1111\u20131119 (2015).","journal-title":"J. Infect. Dis."},{"key":"430_CR42","doi-asserted-by":"publisher","unstructured":"Tan, J. et al. Functional human IgA targets a conserved site on malaria sporozoites. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abg2344 (2021).","DOI":"10.1126\/scitranslmed.abg2344"},{"key":"430_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","volume":"34","author":"MO Mohsen","year":"2017","unstructured":"Mohsen, M. O., Zha, L., Cabral-Miranda, G. & Bachmann, M. F. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin. Immunol. 34, 123\u2013132 (2017).","journal-title":"Semin. Immunol."},{"key":"430_CR44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann, M. F. & Jennings, G. T. Vaccine delivery: A matter of size, geometry, kinetics, and molecular patterns. Nat. Rev. Immunol. 10, 787\u2013796 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"430_CR45","doi-asserted-by":"publisher","first-page":"586","DOI":"10.4161\/hv.27567","volume":"10","author":"JK Mallajosyula","year":"2014","unstructured":"Mallajosyula, J. K. et al. Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge. Hum. Vaccines Immunother. 10, 586\u2013595 (2014).","journal-title":"Hum. Vaccines Immunother."},{"key":"430_CR46","doi-asserted-by":"publisher","first-page":"e0130858","DOI":"10.1371\/journal.pone.0130858","volume":"10","author":"S Banik","year":"2015","unstructured":"Banik, S. et al. Development of a multivalent subunit vaccine against tularemia using Tobacco Mosaic Virus (TMV) based delivery system. PLoS One 10, e0130858 (2015).","journal-title":"PLoS One"},{"key":"430_CR47","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1016\/j.vaccine.2016.09.063","volume":"34","author":"PM Arnaboldi","year":"2016","unstructured":"Arnaboldi, P. M. et al. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague. Vaccine 34, 5768\u20135776 (2016).","journal-title":"Vaccine"},{"key":"430_CR48","doi-asserted-by":"publisher","first-page":"e0194614","DOI":"10.1371\/journal.pone.0194614","volume":"13","author":"AA McCormick","year":"2018","unstructured":"McCormick, A. A. et al. Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge. PLoS One 13, e0194614 (2018).","journal-title":"PLoS One"},{"key":"430_CR49","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3389\/fmicb.2018.01195","volume":"9","author":"AA Mansour","year":"2018","unstructured":"Mansour, A. A. et al. An improved Tobacco mosaic Virus (TMV)-conjugated multiantigen subunit vaccine against respiratory tularemia. Front. Microbiol. 9, 1195 (2018).","journal-title":"Front. Microbiol."},{"key":"430_CR50","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3762\/bjnano.7.54","volume":"7","author":"C Koch","year":"2016","unstructured":"Koch, C. et al. Novel roles for well-known players: from tobacco mosaic virus pests to enzymatically active assemblies. Beilstein J. Nanotechnol. 7, 613\u2013629 (2016).","journal-title":"Beilstein J. Nanotechnol."},{"key":"430_CR51","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.3390\/v6041789","volume":"6","author":"NV Petukhova","year":"2014","unstructured":"Petukhova, N. V., Gasanova, T. V., Ivanov, P. A. & Atabekov, J. G. High-level systemic expression of conserved influenza epitope in plants on the surface of rod-shaped chimeric particles. Viruses 6, 1789\u20131800 (2014).","journal-title":"Viruses"},{"key":"430_CR52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1021\/nl9032395","volume":"10","author":"MT Dedeo","year":"2010","unstructured":"Dedeo, M. T., Duderstadt, K. E., Berger, J. M. & Francis, M. B. Nanoscale protein assemblies from a circular permutant of the tobacco mosaic virus. Nano Lett. 10, 181\u2013186 (2010).","journal-title":"Nano Lett."},{"key":"430_CR53","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1016\/j.vaccine.2017.05.070","volume":"35","author":"CJ Genito","year":"2017","unstructured":"Genito, C. J. et al. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. Vaccine 35, 3865\u20133874 (2017).","journal-title":"Vaccine"},{"key":"430_CR54","doi-asserted-by":"publisher","unstructured":"Wan, Y. et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J. Virol. https:\/\/doi.org\/10.1128\/jvi.02015-19 (2020).","DOI":"10.1128\/jvi.02015-19"},{"key":"430_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1186-4","volume":"16","author":"I Ubillos","year":"2018","unstructured":"Ubillos, I. et al. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S\/AS01E vaccination in African children. BMC Med. 16, 197 (2018).","journal-title":"BMC Med."},{"key":"430_CR56","doi-asserted-by":"publisher","first-page":"e101783","DOI":"10.1371\/journal.pone.0101783","volume":"9","author":"K Gandhi","year":"2014","unstructured":"Gandhi, K. et al. Variation in the circumsporozoite protein of Plasmodium falciparum: Vaccine development implications. PLoS One 9, e101783 (2014).","journal-title":"PLoS One"},{"key":"430_CR57","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1128\/CVI.00066-13","volume":"20","author":"MD Porter","year":"2013","unstructured":"Porter, M. D. et al. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint. Clin. Vaccine Immunol. 20, 803\u2013810 (2013).","journal-title":"Clin. Vaccine Immunol."},{"key":"430_CR58","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.vaccine.2020.12.055","volume":"39","author":"S Chaudhury","year":"2021","unstructured":"Chaudhury, S. et al. Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine. Vaccine 39, 968\u2013975 (2021).","journal-title":"Vaccine"},{"key":"430_CR59","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","volume":"373","author":"DE Neafsey","year":"2015","unstructured":"Neafsey, D. E. et al. Genetic diversity and protective efficacy of the RTS,S\/AS01 malaria vaccine. N. Engl. J. Med. 373, 2025\u20132037 (2015).","journal-title":"N. Engl. J. Med."},{"key":"430_CR60","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","volume":"374","author":"A Olotu","year":"2016","unstructured":"Olotu, A. et al. Seven-year efficacy of RTS,S\/AS01 malaria vaccine among young African children. N. Engl. J. Med. 374, 2519\u20132529 (2016).","journal-title":"N. Engl. J. Med."},{"key":"430_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24585-8","volume":"8","author":"JC Pringle","year":"2018","unstructured":"Pringle, J. C. et al. RTS,S\/AS01 malaria vaccine mismatch observed among Plasmodium falciparum isolates from southern and central Africa and globally. Sci. Rep. 8, 6622 (2018).","journal-title":"Sci. Rep."},{"key":"430_CR62","doi-asserted-by":"publisher","first-page":"e0124856","DOI":"10.1371\/journal.pone.0124856","volume":"10","author":"DC Whitacre","year":"2015","unstructured":"Whitacre, D. C. et al. P. falciparum and P. vivax Epitope-focused VLPs elicit sterile immunity to blood stage infections. PLoS One 10, e0124856 (2015).","journal-title":"PLoS One"},{"key":"430_CR63","doi-asserted-by":"publisher","unstructured":"Thai, E. et al. A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20200061 (2020).","DOI":"10.1084\/jem.20200061"},{"key":"430_CR64","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa2034031","volume":"385","author":"MR Gaudinski","year":"2021","unstructured":"Gaudinski, M. R. et al. A monoclonal antibody for malaria prevention. N. Engl. J. Med. 385, 803\u2013814 (2021).","journal-title":"N. Engl. J. Med."},{"key":"430_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00372-x","volume":"6","author":"KE Seaton","year":"2021","unstructured":"Seaton, K. E. et al. Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection. NPJ Vaccines 6, 110 (2021).","journal-title":"NPJ Vaccines"},{"key":"430_CR66","doi-asserted-by":"publisher","first-page":"e1008373","DOI":"10.1371\/journal.ppat.1008373","volume":"16","author":"D Oyen","year":"2020","unstructured":"Oyen, D. et al. Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein. PLoS Pathog. 16, e1008373 (2020).","journal-title":"PLoS Pathog."},{"key":"430_CR67","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fimmu.2017.00238","volume":"8","author":"JJ Bergstr\u00f6m","year":"2017","unstructured":"Bergstr\u00f6m, J. J., Xu, H. & Heyman, B. Epitope-specific suppression of IgG responses by passively administered specific IgG: Evidence of epitope masking. Front. Immunol. 8, 238 (2017).","journal-title":"Front. Immunol."},{"key":"430_CR68","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.chom.2020.07.001","volume":"28","author":"HA McNamara","year":"2020","unstructured":"McNamara, H. A. et al. Antibody feedback limits the expansion of B cell responses to malaria vaccination but drives diversification of the humoral response. Cell Host Microbe 28, 572\u2013585 (2020). e577.","journal-title":"Cell Host Microbe"},{"key":"430_CR69","doi-asserted-by":"publisher","first-page":"108996","DOI":"10.1016\/j.celrep.2021.108996","volume":"35","author":"D Chatterjee","year":"2021","unstructured":"Chatterjee, D. et al. Avid binding by B cells to the Plasmodium circumsporozoite protein repeat suppresses responses to protective subdominant epitopes. Cell Rep. 35, 108996 (2021).","journal-title":"Cell Rep."},{"key":"430_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00272-6","volume":"6","author":"JM Calvo-Calle","year":"2021","unstructured":"Calvo-Calle, J. M., Mitchell, R., Altszuler, R., Othoro, C. & Nardin, E. Identification of a neutralizing epitope within minor repeat region of Plasmodium falciparum CS protein. NPJ Vaccines 6, 10 (2021).","journal-title":"NPJ Vaccines"},{"key":"430_CR71","doi-asserted-by":"publisher","first-page":"109489","DOI":"10.1016\/j.celrep.2021.109489","volume":"36","author":"K Vijayan","year":"2021","unstructured":"Vijayan, K. et al. Antibody interference by a non-neutralizing antibody abrogates humoral protection against Plasmodium yoelii liver stage. Cell Rep. 36, 109489 (2021).","journal-title":"Cell Rep."},{"key":"430_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21221-4","volume":"12","author":"T Pholcharee","year":"2021","unstructured":"Pholcharee, T. et al. Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum. Nat. Commun. 12, 1063 (2021).","journal-title":"Nat. Commun."},{"key":"430_CR73","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41590-018-0228-6","volume":"19","author":"IA Cockburn","year":"2018","unstructured":"Cockburn, I. A. & Seder, R. A. Malaria prevention: From immunological concepts to effective vaccines and protective antibodies. Nat. Immunol. 19, 1199\u20131211 (2018).","journal-title":"Nat. Immunol."},{"key":"430_CR74","doi-asserted-by":"publisher","first-page":"e0142035","DOI":"10.1371\/journal.pone.0142035","volume":"10","author":"F Khan","year":"2015","unstructured":"Khan, F. et al. Head-to-head comparison of soluble vs. Qbeta VLP circumsporozoite protein vaccines reveals selective enhancement of NANP repeat responses. PLoS One 10, e0142035 (2015).","journal-title":"PLoS One"},{"key":"430_CR75","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1086\/600120","volume":"200","author":"KE Kester","year":"2009","unstructured":"Kester, K. E. et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: Safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200, 337\u2013346 (2009).","journal-title":"J. Infect. Dis."},{"key":"430_CR76","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.str.2013.08.005","volume":"21","author":"Y Song","year":"2013","unstructured":"Song, Y. et al. High-resolution comparative modeling with RosettaCM. Structure 21, 1735\u20131742 (2013).","journal-title":"Structure"},{"key":"430_CR77","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/prot.22540","volume":"77","author":"S Raman","year":"2009","unstructured":"Raman, S. et al. Structure prediction for CASP8 with all-atom refinement using Rosetta. Proteins 77, 89\u201399 (2009).","journal-title":"Proteins"},{"key":"430_CR78","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/prot.21636","volume":"69","author":"R Das","year":"2007","unstructured":"Das, R. et al. Structure prediction for CASP7 targets using extensive all-atom refinement with Rosetta@home. Proteins 69, 118\u2013128 (2007).","journal-title":"Proteins"},{"key":"430_CR79","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1128\/IAI.00866-09","volume":"78","author":"S Dutta","year":"2010","unstructured":"Dutta, S. et al. Alanine mutagenesis of the primary antigenic escape residue cluster, c1, of apical membrane antigen 1. Infect. Immun. 78, 661\u2013671 (2010).","journal-title":"Infect. Immun."},{"key":"430_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-394","volume":"12","author":"X Zou","year":"2013","unstructured":"Zou, X., House, B. L., Zyzak, M. D., Richie, T. L. & Gerbasi, V. R. Towards an optimized inhibition of liver stage development assay (ILSDA) for Plasmodium falciparum. Malar. J. 12, 394 (2013).","journal-title":"Malar. J."},{"key":"430_CR81","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.1016\/j.vaccine.2015.09.001","volume":"33","author":"Z Beck","year":"2015","unstructured":"Beck, Z. et al. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine 33, 5578\u20135587 (2015).","journal-title":"Vaccine"},{"key":"430_CR82","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/14760584.2020.1745636","volume":"19","author":"CR Alving","year":"2020","unstructured":"Alving, C. R., Peachman, K. K., Matyas, G. R., Rao, M. & Beck, Z. Army Liposome Formulation (ALF) family of vaccine adjuvants. Expert Rev. Vaccines 19, 279\u2013292 (2020).","journal-title":"Expert Rev. Vaccines"},{"key":"430_CR83","doi-asserted-by":"publisher","first-page":"47613","DOI":"10.1074\/jbc.M208453200","volume":"277","author":"R Tewari","year":"2002","unstructured":"Tewari, R., Spaccapelo, R., Bistoni, F., Holder, A. A. & Crisanti, A. Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity. J. Biol. Chem. 277, 47613\u201347618 (2002).","journal-title":"J. Biol. Chem."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00430-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00430-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00430-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T09:31:49Z","timestamp":1669282309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00430-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00430-y","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"24 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors S.D., A.B., F.K., and M.L. have filed a patent for the TMV particle technology. The material has been reviewed by the Walter Reed Army Institute of Research and the US Agency for International Development. There is no objection to its presentation and\/or publication. The opinions or assertions contained herein are the private views of the author and are not to be construed as official, or as reflecting true views of the Department of the Army, the Department of Defense, or the US Agency for International Development.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}